stockrowBausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation (BLCO) EPS (diluted)
Bausch + Lomb Corporation's EPS (diluted) for fiscal 2025 was −$1.02, compared with −$0.90 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.30. Over the past ten years it has ranged from −$1.02 (fiscal 2025) to $0.55 (fiscal 2021) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 4 consecutive fiscal years. Bausch + Lomb Corporation ranks 31st of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.02 | — |
| FY2024 | −$0.90 | — |
| FY2023 | −$0.74 | — |
| FY2022 | $0.02 | (96.37%) |
| FY2021 | $0.55 | — |
| FY2020 | −$0.05 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.10 | — |
| Jun 2026 | −$0.04 | — |
| Mar 2026 | −$0.20 | — |
| Dec 2025 | −$0.16 | — |
| 19 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALGN Align Technology, Inc. compare | $6.87 |
| ATR AptarGroup, Inc. compare | $4.12 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| MMSI Merit Medical Systems, Inc. compare | $2.66 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation compare | −$0.21 |
| BLCO Bausch + Lomb Corporation | −$0.30 |
| MMED MiniMed Group, Inc. compare | −$0.59 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BLCO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement